(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Related Questions
How will the dilution from the underwritten offering affect ARTL's earnings per share and valuation multiples?
What pricing range and underwriting terms are expected, and how might they influence the stock's immediate trading range?
What is the intended use of proceeds, and how does this capital raise position Artelo Biosciences relative to its pipeline milestones and peer financing activities?